In Vitro-Generated DC with Tolerogenic Functions: Perspectives for In Vivo Cellular Therapy

Methods in Molecular Biology

Volumn 677, Issue , 2011, Pages 149-159

  van Kooten, Cees ^a   Gelderman, Kyra A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Dexamethasone; Human; Rat; Tolerance

Indexed keywords

CYTOKINE; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; ORGANIC COMPOUND; TOLEROGEN;

ANIMAL; ARTICLE; BIOLOGICAL THERAPY; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTERNATIONAL COOPERATION; PHYSIOLOGY; RAT; UTILIZATION REVIEW;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DEXAMETHASONE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; ORGANIC CHEMICALS; RATS; TISSUE THERAPY;

EID: 79952201639     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-869-0_10     Document Type: Chapter

References (31)

1. Banchereau, J. and Steinman, R. M. (1998) Dendritic cells and the control of immunity, Nature 392, 245–252.
2. Steinman, R. M. and Banchereau, J. (2007) Taking dendritic cells into medicine, Nature 449, 419–426.
3. Reis, E. and Sousa, C. (2006) Dendritic cells in a mature age, Nat. Rev. Immunol. 6, 476–483.
4. Lutz, M. and Schuler, G. (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23, 445.
5. Steinman, R. M., Hawiger, D., and Nussenzweig, M. C. (2003) Tolerogenic dendritic cells, Annu. Rev. Immunol. 21, 685–711.
6. Hackstein, H. and Thomson, A. W. (2004) Dendritic cells: emerging pharmacological targets of immunosuppressive drugs, Nat. Rev. Immunol. 4, 24–35.
7. Woltman, A. M. and van Kooten, C. (2003) Functional modulation of dendritic cells to suppress adaptive immune responses, J. Leukoc. Biol. 73, 428–441.
8. Adorini, L., Giarratana, N., and Penna, G. (2004) Pharmacological induction of tolerogenic dendritic cells and regulatory T cells, Semin. Immunol. 16, 127–134.
9. Morelli, A. E. and Thomson, A. W. (2007) Tolerogenic dendritic cells and the quest for transplant tolerance, Nat. Rev. Immunol. 7, 610–621.
10. van Kooten, C., Stax, A. S., Woltman, A. M., and Gelderman, K. A. (2009) Handbook of experimental pharmacology “dendritic cells”: the use of dexamethasone in the induction of tolerogenic DCs, Handb. Exp. Pharmacol. 188, 233–249.
11. Piemonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., Leone, B. E., Socci, C., and Di Catlo, V. (1999) Glucocorticoids affect human dendritic cell differentiation and maturation, J. Immunol. 162, 6473–6481.
12. Woltman, A. M., De Fijter, J. W., Kamerling, S. W., Paul, L. C., Daha, M. R., and van Kooten, C. (2000) The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells, Eur. J. Immunol. 30, 1807–1812.
13. Vieira, P. L., Kalinski, P., Wierenga, E. A., Kapsenberg, M. L., and de Jong, E. C. (1998) Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential, J. Immunol. 161, 5245–5251.
14. Rea, D., van Kooten, C., Van Meijgaarden, K. E., Melief, C. J. M., and Offringa, R. (2000) Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen presenting cells that secrete IL-10, Blood 95, 3162–3167.
15. Woltman, A. M., Van der Kooij, S. W., De Fijter, J. W., and van Kooten, C. (2006) Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations, Am. J. Transplant. 6, 2580–2591.
16. Fazekasova, H., Golshayan, D., Read, J., Tsallios, A., Tsang, J. Y., Dorling, A., George, A. J., Lechler, R. I., Lombardi, G., and Mirenda, V. (2009) Regulation of rat and human T-cell immune response by pharmaco-logically modified dendritic cells, Transplantation 87, 1617–1628.
17. Roelen, D. L., Schuurhuis, D. H., van den Boogaardt, D. E., Koekkoek, K., van Miert, P. P., van Schip, J. J., Laban, S., Rea, D., Melief, C. J., Offringa, R., Ossendorp, F., and Claas, F. H. (2003) Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells, Transplantation 76, 1608–1615.
18. Mirenda, V., Berton, I., Read, J., Cook, T., Smith, J., Dorling, A., and Lechler, R. I. (2004) Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation, J. Am. Soc. Nephrol. 15, 987–997.
19. Stax, A. M., Gelderman, K. A., Schlagwein, N., Essers, M. C., Kamerling, S. W., Woltman, A. M., and van Kooten, C. (2008) Induction of donor-specific T-cell hyporesponsiveness using dexamethasone-treated dendritic cells in two fully mismatched rat kidney transplantation models, Transplantation 86, 1275–1282.
20. Gordon, S. and Taylor, P. R. (2005) Monocyte and macrophage heterogeneity, Nat. Rev. Immunol. 5, 953–964.
21. Mosser, D. M. and Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol. 8, 958–969.
22. Vanderheyde, N., Verhasselt, V., Goldman, M., and Willems, F. (1999) Inhibition of human dendritic cell functions by methyl-prednisolone, Transplantation 67, 1342–1347.
23. de Jong, E. C., Vieira, P. L., Kalinski, P., and Kapsenberg, M. L. (1999) Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3, J. Leukoc. Biol. 66, 201–204.
24. de Vries, I, Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P., Ruiter, D. J., Gerritsen, M. J., Croockewit, S., Britten, C. M., Torensma, R., Adema, G. J., Figdor, C. G., and Punt, C. J. (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients, Clin. Cancer Res. 9, 5091–5100.
25. Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J. P., Johnston, D. A., Fay, J., and Banchereau, J. (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity, J. Immunother. 29, 545–557.
26. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells, Nat. Med. 4, 328–332.
27. Emmer, P. M., van der Vlag, J., Adema, G. J., and Hilbrands, L. B. (2006) Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness, Transplantation 81, 1451–1459.
28. van Duivenvoorde, L. M., Han, W. G., Bakker, A. M., Louis-Plence, P., Charbonnier, L. M., Apparailly, F., van der Voort, E. I., Jorgensen, C., Huizinga, T. W., and Toes, R. E. (2007) Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms, J. Immunol. 179, 1506–1515.
29. Woltman, A. M., Massacrier, C., De Fijter, J. W., Caux, C., and van Kooten, C. (2002) Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development, J. Immunol. 168, 6181–6188.
30. Peche, H., Trinite, B., Martinet, B., and Cuturi, M. C. (2005) Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors, Am. J. Transplant. 5, 255–267.
31. Stax, A. M., Crul, C., Kamerling, S. W., Schlagwein, N., van der Geest, R. N., Woltman, A. M., and van Kooten, C. (2008) CD40L stimulation of rat dendritic cells specifically favors the IL-12/IL-10 ratio resulting in a strong T cell stimulatory capacity, Mol. Immunol. 45, 2641–2650.